4.8 Review

The promise and challenge of therapeutic genome editing

Journal

NATURE
Volume 578, Issue 7794, Pages 229-236

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41586-020-1978-5

Keywords

-

Funding

  1. Innovative Genomics Institute
  2. HHMI
  3. Paul Allen Frontiers Group
  4. Defense Advanced Research Projects Agency (DARPA) [HR0011-17-2-0043]
  5. William M. Keck Foundation
  6. Centers for Excellence in Genomic Science of the National Institutes of Health [RM1HG009490]
  7. Somatic Cell Genome Editing Program of the Common Fund of the National Institutes of Health [U01AI142817-02]
  8. National Science Foundation [1817593]
  9. Collaborative MS Research Center Award from the National Multiple Sclerosis Society
  10. Direct For Biological Sciences [1817593] Funding Source: National Science Foundation
  11. Div Of Molecular and Cellular Bioscience [1817593] Funding Source: National Science Foundation

Ask authors/readers for more resources

Genome editing, which involves the precise manipulation of cellular DNA sequences to alter cell fates and organism traits, has the potential to both improve our understanding of human genetics and cure genetic disease. Here I discuss the scientific, technical and ethical aspects of using CRISPR (clustered regularly interspaced short palindromic repeats) technology for therapeutic applications in humans, focusing on specific examples that highlight both opportunities and challenges. Genome editing is-or will soon be-in the clinic for several diseases, with more applications under development. The rapid pace of the field demands active efforts to ensure that this breakthrough technology is used responsibly to treat, cure and prevent genetic disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available